NAVIGATING IPILIMUMAB-INDUCED HYPOPHYSITIS IN ADVANCED HEPATOCELLULAR CARCINOMA: A CLINICAL PERSPECTIVE
Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has marked a significant breakthrough in cancer treatment.Ipilimumab (IPI), an anti-CTLA-4 agent, stands Quad Canes out in this therapeutic landscape.However, its efficacy is not without challenges, among them, immune-related adverse events, especially hypophysitis.In this article,